A detailed history of Bank Of America Corp transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Bank Of America Corp holds 253,527 shares of SRRK stock, worth $7.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
253,527
Previous 238,747 6.19%
Holding current value
$7.14 Million
Previous $4.24 Million 50.21%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.84 - $16.79 $115,875 - $248,156
14,780 Added 6.19%
253,527 $2.11 Million
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $2.66 Million - $3.58 Million
201,449 Added 540.11%
238,747 $4.24 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $78,944 - $246,034
12,108 Added 48.07%
37,298 $701,000
Q2 2023

Aug 14, 2023

SELL
$5.79 - $9.11 $195,632 - $307,808
-33,788 Reduced 57.29%
25,190 $189,000
Q1 2023

May 12, 2023

SELL
$7.36 - $12.72 $7.3 Million - $12.6 Million
-991,653 Reduced 94.39%
58,978 $471,000
Q4 2022

Feb 10, 2023

BUY
$7.02 - $9.76 $7.05 Million - $9.81 Million
1,004,692 Added 2187.01%
1,050,631 $9.51 Million
Q3 2022

Nov 14, 2022

SELL
$5.33 - $11.3 $40,300 - $85,439
-7,561 Reduced 14.13%
45,939 $318,000
Q2 2022

Aug 12, 2022

SELL
$4.66 - $13.96 $518,658 - $1.55 Million
-111,300 Reduced 67.54%
53,500 $293,000
Q1 2022

May 16, 2022

BUY
$11.89 - $24.68 $1.15 Million - $2.38 Million
96,418 Added 141.0%
164,800 $2.12 Million
Q4 2021

Feb 08, 2022

BUY
$24.14 - $35.18 $1.15 Million - $1.67 Million
47,461 Added 226.86%
68,382 $1.7 Million
Q3 2021

Nov 15, 2021

BUY
$27.38 - $42.21 $158,475 - $244,311
5,788 Added 38.25%
20,921 $691,000
Q2 2021

Sep 13, 2021

BUY
$26.34 - $46.62 $398,603 - $705,500
15,133 New
15,133 $438,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $1.45B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.